{"pmid":32413701,"title":"The role of ACEIs/ARBs in COVID-19: Friend or foe?","text":["The role of ACEIs/ARBs in COVID-19: Friend or foe?","Med Hypotheses","Zhou, Zhe","Qiu, Yumin","Tao, Jun","32413701"],"journal":"Med Hypotheses","authors":["Zhou, Zhe","Qiu, Yumin","Tao, Jun"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413701","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109810","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319099891713,"score":9.490897,"similar":[{"pmid":32427636,"title":"ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","text":["ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","Cardiol Rev","Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela","32427636"],"journal":"Cardiol Rev","authors":["Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427636","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/CRD.0000000000000319","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837748310017,"score":83.88444},{"pmid":32415832,"title":"COVID-19 and ACEI/ARB: NOT ASSOCIATED?","text":["COVID-19 and ACEI/ARB: NOT ASSOCIATED?","Am J Hypertens","Hajra, Adrija","Bandyopadhyay, Dhrubajyoti","32415832"],"journal":"Am J Hypertens","authors":["Hajra, Adrija","Bandyopadhyay, Dhrubajyoti"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415832","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/ajh/hpaa076","keywords":["acei/arb","covid-19","hypertension"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666991242694623232,"score":76.22359},{"pmid":32415836,"title":"Response to COVID-19 and ACEI/ARB: NOT ASSOCIATED?","text":["Response to COVID-19 and ACEI/ARB: NOT ASSOCIATED?","Am J Hypertens","Schiffrin, Ernesto L","Flack, John M","Ito, Sadayoshi","Muntner, Paul","Webb, R Clinton","32415836"],"journal":"Am J Hypertens","authors":["Schiffrin, Ernesto L","Flack, John M","Ito, Sadayoshi","Muntner, Paul","Webb, R Clinton"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415836","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/ajh/hpaa077","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666991242708254721,"score":72.761314},{"pmid":32340044,"title":"The ACE-2 in COVID-19: Foe or Friend?","text":["The ACE-2 in COVID-19: Foe or Friend?","COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19.","Horm Metab Res","Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O","32340044"],"abstract":["COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19."],"journal":"Horm Metab Res","authors":["Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32340044","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1055/a-1155-0501","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494297178112,"score":68.904625},{"pmid":32502542,"pmcid":"PMC7266583","title":"The immune system and COVID-19: Friend or foe?","text":["The immune system and COVID-19: Friend or foe?","AIM: Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection caused by SARS-CoV-2, which has been became a global public health challenge. The pathogenesis of this virus is not yet clearly understood, but there is evidence of a hyper-inflammatory immune response in critically ill patients, which leads to acute respiratory distress syndrome (ARDS) and multi-organ failure. MATERIAL AND METHODS: A literature review was performed to identify relevant articles on COVID-19 published up to April 30, 2020. The search resulted in 361 total articles. After reviewing the titles and abstracts for inclusion, some irrelevant papers were excluded. Additional relevant articles were identified from a review of citations referenced. KEY FINDINGS: SARS-CoV-2, directly and indirectly, affects the immune system and avoids being eliminated in early stages. On the other hand, the secretion of inflammatory cytokines creates critical conditions that lead to multi-organ failure. SIGNIFICANCE: The immune system which is affected by the virus tries to respond via a cytokine storm and hyperinflammation, which itself leads to further multi-organ damage and even death.","Life Sci","Yazdanpanah, Fereshteh","Hamblin, Michael R","Rezaei, Nima","32502542"],"abstract":["AIM: Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection caused by SARS-CoV-2, which has been became a global public health challenge. The pathogenesis of this virus is not yet clearly understood, but there is evidence of a hyper-inflammatory immune response in critically ill patients, which leads to acute respiratory distress syndrome (ARDS) and multi-organ failure. MATERIAL AND METHODS: A literature review was performed to identify relevant articles on COVID-19 published up to April 30, 2020. The search resulted in 361 total articles. After reviewing the titles and abstracts for inclusion, some irrelevant papers were excluded. Additional relevant articles were identified from a review of citations referenced. KEY FINDINGS: SARS-CoV-2, directly and indirectly, affects the immune system and avoids being eliminated in early stages. On the other hand, the secretion of inflammatory cytokines creates critical conditions that lead to multi-organ failure. SIGNIFICANCE: The immune system which is affected by the virus tries to respond via a cytokine storm and hyperinflammation, which itself leads to further multi-organ damage and even death."],"journal":"Life Sci","authors":["Yazdanpanah, Fereshteh","Hamblin, Michael R","Rezaei, Nima"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502542","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.lfs.2020.117900","keywords":["acute respiratory distress syndrome","covid-19","cytokine storm","hyperinflammation","immune system"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966397812737,"score":65.8626}]}